Last Price
20.98
Today's Change
-0.105 (0.49%)
Day's Change
20.45 - 21.11
Trading Volume
174,744
Market Cap
2 Billion
Shares Outstanding
127 Million
Avg Volume
461,663
Avg Price (50 Days)
20.16
Avg Price (200 Days)
17.52
PE Ratio
17.48
EPS
1.20
Earnings Announcement
29-Jul-2024
Previous Close
21.09
Open
21.10
Day's Range
20.45 - 21.11
Year Range
10.02 - 25.95
Trading Volume
174,858
1 Day Change
-0.52%
5 Day Change
3.35%
1 Month Change
10.89%
3 Month Change
2.14%
6 Month Change
42.14%
Ytd Change
-15.47%
1 Year Change
42.72%
3 Year Change
1578.40%
5 Year Change
1773.21%
10 Year Change
1356.94%
Max Change
193.84%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.